Intravenous Immunoglobulin Market Growth Forecast: Exploring Trends and Opportunities for the Next Decade
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What fueled the previous growth in the intravenous immunoglobulin market?
In recent years, the market size for intravenous immunoglobulin has been on a robust ascend. It is projected to increase from $14.66 billion in 2024 to $15.72 billion in 2025, demonstrating a Compound Annual Growth Rate (CAGR) of 7.2%. The historic surge in growth could be traced back to its application in treating primary immunodeficiency disorders and managing neurological disorders. Other factors that fueled its growth include a rise in the elderly population, advancement in plasma fractionation techniques, expanded neurological indications, treatments of infectious diseases and immunodeficiency treatments in children.
What will be the intravenous immunoglobulin market size in the future?
Strong expansion is predicted for the intravenous immunoglobulin market in the forthcoming years, with its size anticipated to reach $22.01 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 8.8%. The projected growth for the forecast period is attributable to the escalating occurrence of autoimmune diseases, ongoing investigations in the field of immunology, increasing healthcare expenditures, the prevalence of cancer, advancements in immunoglobulin products, and the application of personalized medicine methodologies. Key trends envisioned for the forecast period encompass treatment for primary immunodeficiency disorders (PIDD), accelerated technological innovation, strategic collaborations and partnerships, progress in manufacturing processes, implications in neurology, utilization in hematology and developments in immunotherapy.
Get your intravenous immunoglobulin market report here!
https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report
What main drivers are fueling expansion in the intravenous immunoglobulin market?
The rise in the geriatric population is anticipated to propel the intravenous immunoglobulin market’s growth. The geriatric population is defined as individuals aged 65 and above. As they age, their immune response becomes less efficient, leading to a deficiency in antibodies. Consequently, they require immunoglobulins to fill this gap. This necessitates a greater demand for intravenous immunoglobulins thus fueling the intravenous immunoglobulin market’s expansion. For instance, the Population Reference Bureau, a nonprofit organization based in Kenya, forecasted in January 2024, that the American population aged 65 and older will escalate from 58 million in 2022 to 82 million by 2050, marking a 47% surge. This demographic’s proportion within the overall population is also set to increase from 17% to 23% within the same timeframe. Therefore, the growing geriatric population will significantly contribute to the advancement of the intravenous immunoglobulin market.
What key areas define the segmentation of the global intravenous immunoglobulin market?
The intravenous immunoglobulin market covered in this report is segmented –
1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D)
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications
4) By End-User: Hospitals, Clinics, Home Care
Subsegments:
1) By Immunoglobulin G (IgG): Normal IgG, Specific IgG
2) By Immunoglobulin M (IgM): Normal IgM, Specific IgM
3) By Immunoglobulin A (IgA): Normal IgA, Specific IgA
4) By Immunoglobulin E (IgE): Normal IgE, Specific IgE
5) By Immunoglobulin D (IgD): Normal IgD, Specific IgD
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp
Who are the dominant players expanding their reach in the intravenous immunoglobulin market?
Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.
How are evolving market trends shaping intravenous immunoglobulin Strategies?
The intravenous immunoglobulin market is seeing a surge of innovative products as a leading trend. Major players in this market are striving to cement their position by introducing novel products like liquid immune globulin formulations for combating immunodeficiency diseases. For example, GC Pharma, a pharmaceutical firm based in South Korea, received approval from the US Food and Drug Administration (FDA) in December 2023 for Alyglo, a ready-to-use, sterile liquid formulation. Comprising 10% immunoglobulin G (IgG), it provides 100 mg/mL of protein, 96% of which is human IgG sourced from pooled human plasma. Alyglo is specifically designed for primary humoral immunodeficiency (PI) treatment in adults who are 17 years and above. It is applicable for conditions such as congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiency (SCID).
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8538
Which regions are emerging as leaders in the intravenous immunoglobulin market?
North America was the largest region in the intravenous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Immunochemistry Diagnostic Devices And Equipment Global Market Report 2024
Immunofluorescence Assay Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/immunofluorescence-assay-global-market-report
Immunoglobulins Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
